# Rockwell Medical, Inc. (RMTI)

> Source: Nexqual · https://nexqual.com/RMTI · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Rockwell Medical, Inc. (RMTI), nexqual.com/RMTI" · informational, not investment advice.

**Price:** USD 7.98 (+3.64% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 7.7 · day 7.36–8.24 · 52w 4.89–12.9 · market cap $32.2M · NCM

## Key facts
- Analysts: Buy (mean 1.50 on a 1–5 scale) (2 analysts), mean target USD 20 (range 20–20).
- Total return with dividends: 1Y -32.9% vs S&P 500 +18.1%; 5Y -87.9% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.18, revenue estimate $18.2M.

## Analysts
Consensus Buy (mean 1.50 on a 1–5 scale), 2 analysts; mean target USD 20 (low 20, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-11 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| 2026-07-09 | HC Wainwright & Co. | Target raised | Buy | $2 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -32.9% | -87.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -33.0% | -34.4% |
| Volatility (annualized) | 65.5% | 94.6% |
| Max drawdown | -58.8% (Jan 2026→Jul 2026) | -91.6% (Oct 2021→Jun 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/RMTI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt